BiovelocITA
BiovelocITA is the first Italian biotech accelerator, founded in 2015 by Sofinnova Partners and dedicated to transforming promising research into breakthrough biotech companies. The accelerator was co-founded and will be managed by two Italian repeat entrepreneurs with an outstanding track record: Silvano Spinelli, Chairman, and Gabriella Camboni, CEO. Silvano and Gabriella founded EOS, which they sold in 2013 to Clovis Oncology for $470 million. Prior to that they founded Novuspharma, which went public on the Italian Nuovo Mercato in 2000. Sofinnova Partners invested and backed both companies from the start. BiovelocITA brings together best-in-class scientists, entrepreneurs and investors to foster the development of pioneering companies.
Sector
Biopharmaceuticals
Location
Milan
Strategy
Biovelocita
Website
www.biovelocita.com
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.